Satsuma Pharmaceuticals

General Information


We are a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine. Our product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. DHE products have long been recommended as a first-line therapeutic option for the acute treatment of migraine and have significant advantages over other therapeutics for many patients. However, broad use has been limited by invasive and burdensome administration and/or sub-optimal clinical performance of available injectable and liquid nasal spray products. STS101 is specifically designed to deliver the advantages of DHE while overcoming these shortcomings.

Employees: 11
Founded: 2016
Contact Information
Address 400 Oyster Point Boulevard, Suite 221, South San Francisco, CA 94080, US
Phone Number (650) 410-3200
Web Address
View Prospectus: Satsuma Pharmaceuticals
Financial Information
Market Cap $249.1mil
Revenues $0 mil (last 12 months)
Net Income $-13.0 mil (last 12 months)
IPO Profile
Symbol STSA
Exchange NASDAQ
Shares (millions): 5.5
Price range $15.00 - $15.00
Est. $ Volume $82.5 mil
Manager / Joint Managers Credit Suisse/ SVB Leerink/ Evercore
CO-Managers -
Expected To Trade: 9/13/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change